Using physician work relative value units to profile surgical packages: methods and results for kidney transplant surgery.

BACKGROUND: This investigation outlines an approach for using the physician work relative value units (RVUs) in the Medicare Fee Schedule (MFS) to profile physician clinical activities. These techniques were then used to profile the physician services associated with kidney transplant patients at Emory University System of Health Care. METHODS: All physician services associated with 179 patients who had kidney transplant surgery in 1993 were studied. By using billing data, physician work RVUs were assigned to each service and the results were analyzed by type of service and the hospital department providing the service for physician work RVUs and physician charges. RESULTS: A mean of 130.4 physician work RVUs were involved in the 179 episodes of care. Surgical services represented 48.7% of the physician work activity in the kidney transplant. Visit and consultative services make up the next highest share with 25.5% of the physician work RVUs, whereas anesthesia makes up 13.3% of physician work RVUs. Physician charges totaled $16,249 for kidney transplants in 1993 dollars. Surgical services accounted for 54.2% of physician charges connected with kidney transplants, whereas visits and consultative services represented 20.6% of physician charges. CONCLUSIONS: Physician work RVUs in the MFS offer a unique and much needed perspective on physician clinical activities. Physician work RVUs are an important new tool for healthcare and researchers and their use needs to be more fully explored and benchmarks developed for all major medical and surgical services.

Gadoteridol-enhanced MR imaging of malignant hepatic tumors: effects of triple versus standard doses on lesion-liver contrast.

OBJECTIVE: The purpose of this study was to compare liver signal-to-noise ratio (SNR), lesion SNR, and lesion-liver contrast-to-noise-ratio (CNR) in patients with malignant liver lesions after the administration of a standard dose (0.1 mmol/kg of body weight) or a triple dose (0.3 mmol/kg) of a gadolinium chelate (gadoteridol). We hypothesized that the higher dose would produce a higher lesion-liver CNR and therefore increase the conspicuity of hepatic lesions. MATERIALS AND METHODS: A total of 85 patients with malignant hepatic masses (61 metastases, 22 hepatocellular carcinomas, and two lymphomas) proved by histologic or follow-up studies underwent MR imaging at 1.5 T. T1-weighted spin-echo imaging and gradient-echo imaging were done before and within 1 min after (gradient echo) as well as 5 (spin echo) and 15 (spin echo) min after the injection of 0.1 or 0.3 mmol of gadoteridol per kg, randomized before the start of the study (39 patients received the standard dose, and 46 received the triple dose). The signal intensities of the liver and lesions and the SD of background noise were measured by use of regions of interest to calculate the SNR of the liver and malignant lesions and the lesion-liver CNR. RESULTS: The lesion-liver CNR was increased significantly at 5 and 15 min after the administration of gadoteridol. No significant differences in the liver SNR, lesion SNR, and lesion-liver CNR (after 1 min: standard dose, -5 +/- 8, and triple dose, -4 +/- 14; after 5 min: standard dose, -1 +/- 5, and triple dose, 2 +/- 8; and after 15 min: standard dose, 1 +/- 5, and triple dose, 6 +/- 20) were found between the doses at all time points. CONCLUSION: Triple-dose gadoteridol does not improve the lesion-liver contrast of malignant hepatic lesions over that provided by the standard dose and is not warranted for liver MR imaging.

Does CTAP prior to hepatic resection improve patient survival rates?

The purpose of our study was to compare survival rates of colon carcinoma patients who had undergone attempted curative hepatic resection based on liver staging by computed tomographic angiography (CTA) or portography (CTAP) with previously reported survival rates of patients who underwent similar surgery without preoperative CTAP evaluations. A total of 404 CTAP studies performed at three institutions were reviewed. Of this group, 197 had colon carcinoma. Sixty-nine of the colon patients went to surgery. Actuarial adjusted yearly survival rates were calculated for the prior CTAP colon group and compared to historical controls. The control survival data were taken from reports published prior to the CTAP era. Our study demonstrated no difference in the 1-year survival data between the groups. However, the CTAP patients had greater survival in years 2-4. This greater survival may be multifactorial but in part due to better surgical selection caused by CTAP.

CT angiography and CT arterial portography in evaluation of hepatic adenomas.

OBJECTIVE: Our goal was to evaluate the contribution of CT arterial portography (CTAP) and CT angiography to accurate determination of disease extent in patients with known hepatic adenomas. MATERIALS AND METHODS: Imaging results were reviewed in three women with known hepatic adenomas, all of whom had percutaneous biopsy to confirm the diagnosis. Results of CTAP studies in all patients as well as results of CT arteriography in one patient were compared with routine dynamic CT studies in all three and with MRI studies in two. RESULTS: The CTAP and CT arteriography demonstrated multiple additional lesions in all patients as compared with routine dynamic CT and MRI studies. In one of the patients who was found to have hepatic adenomatosis, the degree of tumor involvement changed the operative procedure from partial hepatectomy to liver transplantation. CONCLUSION: In patients with known hepatic adenomas who require surgery, CTAP provides more accurate preoperative staging of extent of liver replacement with tumor.

Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging.

PURPOSE: To evaluate prospectively the diagnostic accuracy of non-enhanced and gadolinium-enhanced magnetic resonance (MR) imaging in characterization of hepatic lesions. MATERIALS AND METHODS: Fifty-five patients with benign and 52 patients with malignant focal liver lesions underwent examination at 1.5 T that comprised nonenhanced and dynamic contrast material-enhanced images. Four experienced radiologists independently read the different sets of images without and with knowledge of clinical history. RESULTS: Receiver operating characteristic analysis showed that dynamic contrast-enhanced MR imaging added information to nonenhanced MR studies and thereby improved distinction between benign and malignant lesions (P < .05). Knowledge of clinical data further improved lesion characterization with nonenhanced and combined nonenhanced and contrast-enhanced MR imaging (P < .05). CONCLUSION: Dynamic contrast-enhanced MR imaging is a useful adjunct for characterization of hepatic lesions. Knowledge of clinical history still has a decisive effect on interpretation of MR images of the liver.

Combined CT arterial portography and CT hepatic angiography for evaluation of the hepatic resection candidate. Work in progress.

PURPOSE: To determine whether the addition of computed tomographic (CT) angiography to CT arterial portography would improve lesion detection and heighten confidence in interpreting perfusion abnormalities. MATERIALS AND METHODS: The two examinations were performed sequentially in 10 candidates for surgical resection of hepatic tumors. Arterial vascular access was obtained with bilateral punctures of the common femoral artery and selective placement of angiographic catheters in the hepatic artery and superior mesenteric artery (SMA). CT scans were obtained first during injection of contrast material into the SMA, followed by repeated imaging of the liver during injection of contrast material into the hepatic artery. RESULTS: The procedure demonstrated, among other results, three additional lesions in two patients, a possibly nontumorous abnormality as tumorous in one, and a suspected tumorous abnormality as nontumorous in one. Suspected nontumorous abnormalities in four patients were confirmed at CT angiography. CONCLUSION: These preliminary data support a trial of this technique in a larger population.

Contrast-enhanced MR imaging of hepatic lesions treated with percutaneous ethanol ablation therapy.

PURPOSE: Magnetic resonance (MR) images were correlated with results of fine-needle aspiration (FNA) to determine the role of MR imaging in evaluating hepatic neoplasms treated with percutaneous ethanol ablation therapy (PEAT). MATERIALS AND METHODS: Contrast material-enhanced and unenhanced MR images were obtained in 11 patients with hepatic neoplasms before PEAT (13 studies) and at intervals after PEAT (25 studies). FNA was performed at each follow-up visit. RESULTS: After PEAT, the MR appearance of the lesions was extremely variable. Also, the signal characteristics of most lesions did not change significantly with any sequence over time. Of eight lesions that demonstrated contrast enhancement before therapy, four demonstrated persistent enhancement and four showed loss of enhancement. Six of these lesions had no viable tumor at FNA. T2-weighted sequences most often showed mixed signal intensity regardless of T2-weighted imaging appearance before therapy. CONCLUSION: The MR appearance of PEAT-treated hepatic lesions is not a reliable indicator of residual or recurrent tumor.

Preoperative determination of the resectability of hepatic tumors: efficacy of CT during arterial portography.

OBJECTIVE: A multiinstitutional study was performed to evaluate the efficacy of CT during arterial portography for determining the resectability of hepatic tumors. The impact of findings from CT during arterial portography on patients' treatment (i.e., surgical vs nonsurgical) was assessed. In patients considered to have resectable tumors, the accuracy of CT during arterial portography for predicting surgical findings was also evaluated. MATERIALS AND METHODS: A retrospective study was done of 404 patients from three institutions who had CT during arterial portography during the period 1985-1991 as part of preoperative staging to determine the resectability of hepatic tumors. The tumors included metastases from colorectal carcinoma in 197 patients (49%); other hepatic metastases, mostly from adenocarcinoma of the stomach, pancreas, and biliary tree in 123 (30%); and primary hepatocellular carcinoma in 84 (21%). Imaging results were correlated with results of percutaneous biopsy of at least one hepatic lesion in patients whose tumors were considered unresectable. In patients whose tumors were considered resectable, results were correlated with preoperative percutaneous biopsy (obtained in almost all cases) and pathologic examination of a surgical specimen (all cases). Although each case was considered individually, four criteria were used for resectability: (1) accessibility of all lesions to lobar or wedge resection that would yield clear margins, (2) anticipation that residual liver tissue after resection would provide sufficient function, (3) the absence of invasion of central hepatic vascular or biliary structures, and (4) the absence of extrahepatic disease. No specific restriction was made with respect to the number of hepatic lesions present. The accuracy of findings by CT during arterial portography for predicting resectability was assessed in the 146 patients who had tumors that were considered resectable on the basis of imaging findings and had surgery. RESULTS: Of 404 patients, only 146 (36%) were thought to be candidates for resection on the basis of findings from CT during arterial portography. Of these, 122 (84%) actually had resection. The 24 patients who did not have resection included 22 patients with disease understaged or overstaged by CT during arterial portography, one with true-negative findings by CT during arterial portography, and one who died during surgery. The accuracy of findings by CT during arterial portography for predicting results at surgery was 85% for all patients and 91% for the subset of patients who had primary colorectal tumors with hepatic metastases. CONCLUSION: Our experience shows that CT during arterial portography is a useful procedure for assessing the resectability of hepatic tumors. In our study, 64% of patients were spared unnecessary surgery.(ABSTRACT TRUNCATED AT 400 WORDS)

Malignant hepatic tumors: safety of high-dose percutaneous ethanol ablation therapy.

The authors retrospectively analyzed clinical records to determine the safety and complication rate of percutaneous ethanol ablation therapy with more than 10 mL of ethanol administered per session for treatment of malignant hepatic tumors. Ten patients underwent a total of 35 sessions with 10 mL or more of ethanol, and four underwent 18 sessions with 10 mL or less. No serious complications occurred with any dose. Pain and fever were the most common complications at all doses, and the higher frequency of these at larger ethanol volumes may be related to the greater degree of tumor necrosis induced by the larger volume.

Hepatocellular tumors: characterization with Mn-DPDP-enhanced MR imaging.

Fifty-eight patients suspected of having focal hepatic disease were studied prior to and following the intravenous administration of manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (DPDP), a hepatobiliary magnetic resonance (MR) contrast agent. Four doses (3, 5, 8, or 10 mumol/kg) of Mn-DPDP were used to test the hypothesis that Mn-DPDP-enhanced MR imaging would display enhancement in tumors of hepatocellular origin. A total of 203 lesions were evaluated. Histologic proof was available in 32 cases, and in 26 cases lesions were evaluated on the basis of characteristic imaging findings. Statistical calculations for distinction of tumors of hepatocellular origin yielded a sensitivity of 100%, a specificity of 92.0%, an accuracy of 93.6%, a positive predictive value of 75.9%, and a negative predictive value of 100%. The authors conclude that the presence and patterns of enhancement at Mn-DPDP-enhanced MR imaging permit reliable distinction between hepatocellular and nonhepatocellular tumors.

Hepatocellular carcinoma: CT appearance after percutaneous ethanol ablation therapy. Work in progress.

Nine patients with biopsy-proved hepatocellular carcinoma underwent percutaneous ethanol ablation therapy (PEAT) with computed tomographic (CT) guidance. Twenty-five ablation sessions were performed in nine lesions ranging in size from 1.8 to 6.5 cm. Repeat biopsy was performed in seven of those nine lesions between 1 and 2 months after completion of therapy. CT scans obtained immediately after ablation demonstrated a necrotic area equal in size to the target lesion in five patients; four of those five patients have had negative findings at biopsy and are free of known disease. None of the patients with CT evidence of limited necrosis are currently free of disease. Peripheral nodularity was demonstrated after ablation in three patients at CT; none are free of disease. All four patients in whom there was no peripheral nodularity are free of known disease. Thus, CT evidence of necrosis and lack of nodularity immediately after PEAT are suggestive of absence of disease.

Dual contrast enhancement of both T1- and T2-weighted sequences using ultrasmall superparamagnetic iron oxide.

BMS 180549 (previously AMI-227), an ultrasmall superparamagnetic iron particulate agent, was investigated to determine its utility as a contrast agent on T1-weighted, as well as T2-weighted sequences, as a function of route of administration, (intravenous versus selective arterial) and concentration. Twelve farm pigs were divided into three groups of four each by route of administration (intravenous, selective superior mesenteric, or selective hepatic arterial injection). 10 mumol/kg and 20 mumol/kg dosages were given and evaluated both immediately after and 20-24 hr after contrast infusion, using both spin-echo and gradient-echo T1 and T2-weighted sequences. Significant postcontrast liver and spleen enhancement was noted at both concentrations, regardless of route of administration on both T1- and T2-weighted sequences. The earliest postcontrast T1-weighted sequence obtained during the 1-3 min interval following IV administration of high dose (20 mumol/kg) contrast demonstrated an average of +42.8% liver and +249.0% spleen enhancement; 24 hr later this decreased to 0 and 7.2%, respectively. The earliest postcontrast T2-weighted sequence obtained during the 8-17 min interval post high-dose IV contrast showed an average of -75.8% decrease in liver and -28.7% decrease in spleen signal intensity; 24 hr later the magnitude of these changes diminished to -33.1% and +2.5%, respectively. No significant difference was noted in liver or spleen enhancement, regardless of route of contrast administration (intravenous versus intraarterial).

The frequency and significance of small (less than or equal to 15 mm) hepatic lesions detected by CT.

The purpose of our study was to determine the frequency of detection of small hepatic lesions (less than or equal to 15 mm) in outpatients who had abdominal CT and to assess the significance of these lesions in the presence or absence of known malignant tumors. Contrast-enhanced abdominal CT scans in 1454 patients were reviewed. In 254 patients (17%), hepatic lesions 15 mm or smaller were detected. In 51% of these patients, lesions were judged benign on the basis of other imaging studies, biopsy results, or stability for at least 6 months as shown by CT. Lesions were judged malignant on the basis of progression seen on radiologic studies or biopsy in 22%. The other 27% of the patients had lesions that could not be classified. The majority of patients with small hepatic lesions (82%) were known to have a malignant tumor; in 51% of these patients, lesions were diagnosed as benign. No patient without a known malignant tumor had a small hepatic lesion that was determined to be malignant. Multiple small lesions were more likely to represent malignant disease than were single small lesions. We conclude that small hepatic lesions are common (seen in 17% of our patients), and that there is a high probability that hepatic lesions smaller than 15 mm are benign, even in patients known to have an extrahepatic malignant tumor.

Hepatic pseudolesion: appearance of focal low attenuation in the medial segment of the left lobe at CT arterial portography.

Fifty computed tomographic (CT) arterial portography (CTAP) examinations were retrospectively reviewed to determine the prevalence of a pseudolesion, defined as a focal low-attenuation area located in the medial segment of the left hepatic lobe immediately anterior to the porta hepatis. This pseudolesion was considered to be present if the described low-attenuation area was detected with CTAP but was not confirmed with one or more of the following: delayed-iodine hepatic CT (DICT), magnetic resonance (MR) imaging, surgery, and routine follow-up abdominal CT. A pseudolesion was suspected in seven of 50 (14%) cases. Correlation was made with findings at DICT in all seven cases and at MR imaging in five of the seven cases. In addition, correlation with findings at pathologic examination was made in four of the seven cases (57%). Correlation with findings on one or more follow-up abdominal CT scans was also made in three of the seven cases.

Diagnosis of pancreatic transplant dysfunction: value of gadopentetate dimeglumine-enhanced MR imaging.

Sixteen MR studies performed in four patients who had undergone combined pancreatic and renal transplantation were reviewed retrospectively to determine if dynamic gadopentetate dimeglumine-enhanced gradient-echo imaging is useful in the early diagnosis of pancreatic transplant rejection. The MR studies were performed between 3 days and 6 months after transplantation and consisted of T1- and T2-weighted spin-echo images as well as a gradient-echo image prior to administration of an IV bolus of gadopentetate dimeglumine (0.1 mmol/kg). After injection of gadopentetate dimeglumine, a static dynamic gradient-echo scan was obtained. Signal-intensity measurements were determined for each of the gradient-echo images and used to generate an enhancement curve. Because T2 values have previously been used as an objective indicator of rejection, the mean T2 of each pancreatic transplant was calculated also. The MR results were compared with clinical and laboratory data and/or percutaneous biopsy results. In six studies of normally functioning pancreatic allografts, the percent enhancement during the first minute of the enhancement curve was 98 +/- 23% (1 SD). In six episodes of acute dysfunction (rejection or infarction), the first-minute enhancement was 42 +/- 20%. In four cases of dysfunction, the finding of an abnormal enhancement curve preceded a significant drop in urinary amylase by 1-4 days. The calculated T2 value was prolonged in only two cases in which biopsy-proved pancreatic infarction had occurred. No prolongation of T2 was evident in four cases of rejection alone. These results suggest that mean T2 calculation at 1.5 T may not be a reliable indicator of pancreatic transplant rejection, but that gadopentetate dimeglumine-enhanced gradient-echo MR imaging of the pancreatic transplant may be a reliable early indicator of pancreatic transplant dysfunction.

Liver transplant biopsies with a biopsy gun.

The authors evaluated the safety and efficacy of a biopsy gun for performance of image-guided percutaneous biopsy of hepatic allografts in liver transplant recipients. Two hundred fifty-two liver biopsies were performed in 58 transplant recipients over a 27-month period by using this instrument with an 18-gauge needle. Major complications occurred in two of the 252 biopsies (0.8%): One hemopneumothorax necessitated drainage with a chest tube, and one hemorrhage necessitated transfusion. No patient required surgical exploration because of a complication of the biopsy. Specimens were adequate for accurate histopathologic diagnosis in 248 of 252 procedures (98.4%). The authors conclude that image-guided percutaneous biopsy of hepatic allografts with use of the biopsy gun is a safe and accurate method of obtaining hepatic tissue from liver transplant recipients for histopathologic analysis.

Renal transplant rejection. Limited value of duplex Doppler sonography.

Over a two-year period, 275 duplex Doppler ultrasound (US) examinations were performed on 75 renal allograft recipients. Retrospective visual analysis of the Doppler tracings was compared to concurrent clinical findings and to biopsy results. One hundred eight of the 176 Doppler examinations (61%) that showed acute rejection clinically or histologically were interpreted as rejection, while 80 of 99 examinations (81%) in clinically normal patients were interpreted as normal. Two hundred thirty-four examinations had resistive index (RI) calculations. Seventy-two of 141 examinations (51%) with RI less than 0.70 had clinical or biopsy evidence of rejection. Studies compared with only concurrent biopsies revealed that 35 of 39 US examinations interpreted as rejection were confirmed histologically, but only one of 32 examinations that appeared normal sonographically was histologically normal. The low sensitivity of Doppler US, whether by waveform analysis or RI calculation, makes it a poor screening test for acute rejection. The findings support the conclusion that Doppler sonography cannot replace biopsy in the evaluation of renal transplant dysfunction, particularly when the waveform analysis is normal and the RI less than 0.70.

Hepatic dynamic sequential CT: section enhancement profiles with a bolus of ionic and nonionic contrast agents.

The enhancement characteristics in different portions of the liver during dynamic sequential bolus computed tomography (CT) with iodinated contrast material (DSBCT) were prospectively evaluated in 75 patients by using iothalamate meglumine, iopamidol, and iohexol (25 patients received each agent). After baseline noncontrast CT was performed, DSBCT was performed with a 180-mL intravenous bolus administered at 2 mL/sec. Scanning was started 25 seconds after the bolus was initiated, by using a 3-second scan time and rapid cephalocaudal table incrementation, yielding contiguous 8-mm-thick sections at a rate of nine sections per minute. On postcontrast images, peak enhancement was 115% for iopamidol and 117% for iohexol, both of which were superior to iothalamate meglumine at 95% (P less than .05). After peaking, enhancement then decreased for all three contrast agents, although the decline was more precipitous for iothalamate meglumine. Enhancement on the more caudal sections with both iopamidol and iohexol was superior to that with iothalamate meglumine (P less than .05). The data suggest that the enhancement characteristics for the two nonionic agents may be more optimal for detection of focal hepatic lesions than the ionic agent.